Faut-il traiter l'osteoporose liee a la thalassemie majeure: deux cas cliniques [Should we treat thalassemia-induced osteoporosis: two case reports].


Autoria(s): Lucini M.; Stoll D.; Aubry-Rozier B.; Lamy O.
Data(s)

2012

Resumo

We report two cases of beta-thalassemia-induced osteoporosis. A man and a woman presented an osteoporosis at the densitometry and were treated with bisphoshonate iv. All the studies analysed the efficacity of bisphosphonate, in particular zoledronate seems to be effective. Concerning the pathogenesis, the RANK-RANK-Ligand and OPG play a major role in bone-resorption and seem to be the principal implicated mechanism for the development of osteoporosis in BTM. At the moment there is no study evaluating the efficacity of denosumab in the BTM.

Identificador

http://serval.unil.ch/?id=serval:BIB_CE82E3999E85

isbn:1661-8157 (Print)

pmid:23032499

doi:10.1024/1661-8157/a001076

Idioma(s)

fr

Fonte

Praxis, vol. 101, no. 20, pp. 1325-1329

Palavras-Chave #Absorptiometry, Photon; Adult; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/therapeutic use; Bone Density Conservation Agents/adverse effects; Bone Density Conservation Agents/therapeutic use; Diphosphonates/adverse effects; Diphosphonates/therapeutic use; Female; Humans; Hypogonadism/complications; Hypogonadism/drug therapy; Imidazoles/adverse effects; Imidazoles/therapeutic use; Infusions, Intravenous; Male; Osteoporosis/diagnosis; Osteoporosis/drug therapy; beta-Thalassemia/complications; beta-Thalassemia/diagnosis
Tipo

info:eu-repo/semantics/article

article